Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension

NCT00273299 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00273299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00273299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2005
Completion date
July 31, 2006
Enrollment
607 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension